Patient Follow-up

Radiomics.bio is actively working on providing automated image-based endpoints to follow up the evolution of solid tumours in cancer patients. In this framework, we are about to launch our SALMON trial to validate an automatic calculation of the current RECIST v1.1 scoring (aRECIST, mainly looking at tumour size) and to initiate the work on a next generation optimized RECIST scoring (oRECIST, considering the full tumour phenotype).